BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: After normalization of colony counts to the NDC, a significant difference was seen between the healthy and BP-CML samples after MCL-1 (healthy: 77.24 ± 29.85%; BP-CML: 30.49 ± 19.09%; p = 0.0367) or BCL-xL (healthy: 68.32 ± 18.32%; BP-CML: 13.06 ± 7.88; p = 0.012) inhibition, suggesting inhibition of these proteins reduces the ability of BP-CML cells to generate colonies to a greater degree than healthy cells (Fig. 5B).